MedTrace Logo

MT-601 Administered To Patients With Locally Advanced Unresectable or Metastatic Pancreatic Cancer

NCT06549751 · Status: NOT_YET_RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 38

Last updated 2026-05-13

No results posted yet for this study

Summary

The goal of this clinical trial is to assess safety and tolerability of escalating doses of MT-601 administered during the off week of chemotherapy regimen for patients with pancreatic cancer. The main question\[s\] it aims to answer are: safety and efficacy • overall response rate and duration of response. Participants will meet all applicable inclusion criteria prior to chemotherapy and must agree to provide apheresis material.

Conditions

  • Pancreas Cancer
  • Pancreatic Cancer Metastatic
  • Pancreatic Cancer (Unresectable)

Interventions

DRUG

MT-601 dose 200 million cells

MT-601 Dose 200 million cells

DRUG

MT-601 dose 400 million cells

MT-601 Dose 400 million cells

DRUG

MT-601 dose 800 million cells

MT-601 Dose 800 million cells

DRUG

MT-601 dose 1200 million cells

MT-601 Dose 1200 million cells

Sponsors & Collaborators

  • M.D. Anderson Cancer Center

    collaborator OTHER

  • Marker Therapeutics, Inc.

    lead INDUSTRY

Principal Investigators

  • Patricia Allison, BS · Marker Therapeutics

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-07-16
Primary Completion
2028-07-16
Completion
2028-09-16
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06549751 on ClinicalTrials.gov